ESO-101
Eosinophilic Esophagitis (EoE)
Phase 2Active
Key Facts
About EsoCap
EsoCap is a clinical-stage biotech company pioneering a novel drug delivery platform for esophageal diseases. Its core innovation is a mucoadhesive film technology that allows therapeutic agents to adhere to the esophageal wall for extended periods, enabling effective local treatment. The company's lead candidate, ESO-101 for eosinophilic esophagitis (EoE), has successfully completed a Phase II trial and holds FDA Orphan Drug Designation. EsoCap is leveraging its versatile platform to develop treatments for other conditions like reflux disease, Barrett's esophagus, and esophageal cancer.
View full company profileTherapeutic Areas
Other Eosinophilic Esophagitis (EoE) Drugs
| Drug | Company | Phase |
|---|---|---|
| APT-1011 | Ellodi Pharmaceuticals | Phase 3 |
| AQ280 | Aqilion | Phase 1/Preclinical |
| '1104 | Revolo Biotherapeutics | Phase 2 |
| Solrikitug | Uniquity Bio | Phase 2 |
| Cendakimab | Bristol Myers Squibb | Phase 3 |
| Barzolvolimab | Celldex Therapeutics | Phase 2 |
| Vonoprazan | Phathom Pharmaceuticals | Phase 2 |